Evidence map›Paper›PMID 31114016›Full record

ArticleBritish journal of cancer2019

A NOTCH added to metabolomics.

Odd Terje Brustugun

Abstract readEditorialComment
In one paragraph

Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Role of Notch 1 signaling and glycolysis in the pathogenic mechanism of adenomyosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Odd Terje BrustugunSection of Oncology, Drammen Hospital, Vestre Viken Health Trust, Dronninggata 28, N-3004, Drammen, Norway. otr@vestreviken.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deregulated metabolism is a hallmark of cancer. In the accompanying study by Sellers et al. published in the British Journal of Cancer, metabolism-related transcriptomics data from in silico data sets are analysed, with the findings being further investigated in the experiments on tumour tissue slices and finally validated in patients. The study adds to our growing understanding of therapeutically accessible metabolic reprogramming in malignancies.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansMetabolomics

Identifiers

PMID31114016
PMCPMC6738034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.